TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor
Authors:
Open Access
- 14 June 2002
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 21 (27) , 4257-4265
Abstract
We describe a TNF fusion protein designated TNF-Selectokine, which is a homo-trimeric molecule comprised of a single chain antibody (scFv) targeting module, a trimerization domain and TNF. TNF-Selectokine exerts high bioactivity towards the targeted and adjacent, antigen negative cells. Membrane targeting dependent immobilization of the TNF-Selectokine induced cell death in TNFR1 and TNFR2 dependent manner, thus cell bound TNF-Selectokine mimicks membrane TNF. To restrict TNF activity to the tumor, a prototype of a TNF-Selectokine prodrug was constructed by insertion of a TNFR1 fragment, separated from TNF by a protease-sensitive linker. The prodrug exerts minimal TNF activity, but can be activated in vitro several thousand-fold by proteolytic digest, showing the principal feasibility of this approach. Choice of cleavage site(s) recognized by protease(s) typically associated with a given carcinoma should allow high dose systemic application of the respective TNF prodrug that unveils its specific bioactivity only in targeted tissues.Keywords
This publication has 26 references indexed in Scilit:
- Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectivesCurrent Oncology Reports, 2001
- Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)Nature Biotechnology, 2000
- A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivoNature Medicine, 2000
- Deregulation of the signaling pathways controlling urokinase productionEuropean Journal of Biochemistry, 1999
- A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cellsNature, 1997
- The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptorCell, 1995
- Characterization of ligand binding by the human p55 tumour‐necrosis‐factor receptorEuropean Journal of Biochemistry, 1994
- Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activationCell, 1993
- Oligomeric tumour necrosis factor α slowly converts into inactive forms at bioactive levelsBiochemical Journal, 1992
- Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.Proceedings of the National Academy of Sciences, 1990